ClinicalTrials.gg
RecruitingNCT07323524Dapa-Active LNUpdated Nov 6, 2026

Dapagliflozin in Active Lupus Nephritis

A Phase 4 interventional study of Dapagliflozin (10Mg Tab) along with standard medical therapy and Placebo in Lupus Nephritis (LN), sponsored by Brigham and Women's Hospital. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Brigham and Women's Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 6, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Planned enrollment
58th of 100
33 · median 50
Started
2026
with 14 others
Phase 4
7 of 114
3 open now
Primary completion
2028-07
later than 23 of 49 live
Registered
108th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 58th largest by planned enrollment of the 100 interventional ones that give a count, is one of 15 that started in 2026, is one of 7 in phase 4, reaches primary completion later than 23 of the 49 other live ones, and was the 108th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.

Read the detailed description

This is a pilot and feasibility randomized, double-blind, placebo-controlled trial involving patients with active lupus nephritis. It will be a concealed allocation, blinded randomized controlled trial of dapagliflozin 10 mg/day or matched placebo in a 2:1 allocation ratio (22 subjects active arm: 11 subjects placebo arm), in addition to standard-of-care treatment, for 12 weeks. After informed consent, 33 eligible subjects will be randomized 2:1 to oral dapagliflozin 10 mg/day or identical oral placebo/day for 12 weeks. Study visits will occur at screening (Visit -1), baseline (Visit 0) and weeks 4 (Visit 1), 8 (Visit 2) and 12 (Visit 3). Observational data including laboratory test results obtained in routine clinical care will be collected through 12 months of follow-up.

The primary outcomes are:

  1. the overall proportion of identified as potentially eligible/pre-screened patients who enroll in the trial;
  2. feasibility and completeness of data collection procedures;
  3. changes in urine protein-to-creatinine ratio (UPCR) and precision of these estimates from baseline to week 12 in each group; and
  4. rates and proportions of serious adverse events and of adverse events of interest, including genitourinary infections and volume depletion.
03

Conditions studied

  • Lupus Nephritis (LN)

Browse trials for

Keywords

  • dapagliflozin
  • SGLT2 inhibitor
  • safety
  • feasibility
  • pilot trial
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Age 18-70 years, fulfilling 2012 SLICC or 2019 ACR/EULAR criteria for SLE, with -proven class III, IV and/or V LN

      • Active (new or relapsing) LN within the prior six months, with at least one of the following:

        • Kidney biopsy with activity index >2 and/or
        • Active urinary sediment (>5 RBCs, >5 WBCs, or cellular casts)
      • Receiving standard-of-care regimen for active LN, including mycophenolate, cyclophosphamide, belimumab, azathioprine, a calcineurin inhibitor, and/or B cell depleting therapies
      • Recent or ongoing use for active LN within the past 6 months
      • Receiving standard-of-care antimalarial therapy and RAAS blockade, unless
      • Estimated ≥0.5 g/g 24 hr proteinuria or ≥0.3 mg/g 24 hr microalbuminuria at enrollment (on first morning urine)
      • Ability to given

Exclusion criteria

Exclusion Criteria:

  • \< 25 ml/min/1.73m2

    • Acute kidney injury at study enrollment (>50 percent rise in creatinine within 90 days)
    • Type I diabetes, underweight ( \<18.5), active , active infection, or recurrent genitourinary infections
    • For females: pregnancy, or desiring of pregnancy and not using , or unable to use contraception
    • Current use of >1mg/kg/day prednisone equivalent
    • Current or prior use of SGLT2 inhibitors or GLP-1 receptor agonists
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (estimated)

Study arms

  • Active comparator
    Dapagliflozin 10 mg daily

    Subjects will receive masked dapagliflozin 10 mg daily for 12 weeks

    Drug: Dapagliflozin (10Mg Tab) along with standard medical therapy

  • Placebo comparator
    Matching placebo pill daily

    Subjects will receive a matching placebo pill to take daily for 12 weeks

    Drug: Placebo

Interventions

  • DrugDapagliflozin (10Mg Tab) along with standard medical therapy

    Drug page: DapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pilot and feasibility of adding dapagliflozin to standard medical therapy in active lupus nephritis (LN)

  • DrugPlacebo

    Matching placebo daily with standard of care

06

What researchers measure

Primary outcomes

  1. Proportion of eligible enrolled

    The overall proportion of identified as potentially eligible/pre-screened patients who enroll in the trial

    Time frame: 3 years

Secondary outcomes

  1. Feasibility of data collection

    We will assess the percent of missing data elements overall at pilot trial completion.

    Time frame: 3 years

Other outcomes

  1. Change in urine protein-to-creatinine ratio

    Change in urine protein-to-creatinine ratio (UPCR) from baseline to week 12 in each group

    Time frame: 12 weeks per subject

  2. Adverse outcomes

    Rates and proportions of serious adverse events and of adverse events of interest, including genitourinary infections and volume depletion

    Time frame: 3 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2026 (actual). Primary completion is estimated for Jul 2028, 25 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jul 2029 → Jul 2028 and completion Jan 2030 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 7, 2026
StartActual
May 22, 2026
Primary completionEst.
Jul 1, 2028was Jul 2029
CompletionEst.
Sep 1, 2028was Jan 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 19, 2026→May 22, 2026
Nov 6, 2026
Primary completion
Jul 2029→Jul 1, 2028
Nov 6, 2026
Study completion
Jan 2030→Sep 1, 2028
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Start date May 19, 2026→May 22, 2026
    Primary completion Jul 2029→Jul 1, 2028
    Study completion Jan 2030→Sep 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07323524
Responsible party
Karen H. Costenbader (Associate Physician, Rheumatologist, Brigham and Women's Hospital) — Principal investigator
First posted
Jan 7, 2026
Start date
May 22, 2026
Primary completion
Jul 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Karen H Costenbader, MD, MPH
Contact
kcostenbader@bwh.harvard.edu
(617) 525-8785
April M Jorge, MD
Contact
amjorge@mgh.harvard.edu
617-643-9624

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion